FAP and cancer: As an new dual targeting PET radiotracer, 68Ga‐FAP‐RGD is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga‐FAP‐RGD in patients with various types of cancer and compared them with the results of 68Ga‐FAPI‐02 or 18F‐FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga‐FAP‐RGD.